Live flu vaccine trial
Friday, 27 February, 2009
Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).
The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.
The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.
Antibiotic for drug-resistant bacteria found in plain sight
The antibiotic in question is an intermediate chemical in the natural process that produces the...
No clear link between paracetamol in pregnancy and autism/ADHD
Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
